Clinical trials

Only want trials near your city that fit you? Get alerts

Disease

Country

Status

Phase

Reset

164 trials

NCT07121777
Recruiting
Anti CD19/BCMA CAR Gene Therapy for Autoimmune Diseases
Not applicable · China · 1 site
Registry update: 13 Aug 2025
NCT07182981
Recruiting
Patients Diagnosed With Scleroderma and Their Chewing and Swallowing Performance
Not applicable · 1 site
Registry update: 19 Sept 2025
NCT07104721
Recruiting
A Clinical Study of YTS109 Cell for R/R Autoimmune Diseases
Phase 1 · China · 1 site
Registry update: 21 Oct 2026
NCT07182968
Recruiting
Cultural Adaptation, Validity, and Reliability of the Turkish Version of The PASTUL Questionnaire
Not applicable · 1 site
Registry update: 19 Sept 2025
NCT07183072
Recruiting
Patients Diagnosed With Scleroderma: Physical Performance and Functionality
Not applicable · 1 site
Registry update: 19 Sept 2025
2024-519532-16-00
Recruiting
A phase I/II study of CAR-expressing Allogenic iPSC derived NK cells for treatment of autoiMmune disease by B cELl depletion - CARAMEL
Phase 1/2 · Germany · 1 site
Registry update: 29 May 2026
NCT07052565
Recruiting
CAR-T Cells Therapy for Patients With Autoimmune Diseases
Not applicable · China · 1 site
Registry update: 8 Jul 2025
NCT06991114
Recruiting
AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.
Phase 2 · Bulgaria, Brazil, Germany, Spain, France, Italy, Poland, Portugal, Romania, Serbia, United States · 54 sites
Registry update: 31 Jul 2026
Conflicting statuses (not updated in the registry for 3 months)
NCT06297096
Recruiting
Study of the Efficacy of Nintedanib+Tocilizumab in Patients With Systemic Sclerosis and Interstitial Lung Disease
Phase 3 · Poland · 1 site
Registry update: 8 Apr 2026
NCT06828042
Recruiting
Safety and Efficacy of Universal CD19-targeting CAR-γδT Cells in Refractory Autoimmune Diseases
Phase 1/2 · China · 1 site
Registry update: 22 Sept 2026
NCT07491523
Recruiting
Double Immunosuppression With or Without Anti-fibrotic in Scleroderma ILD
Not applicable · Greece · 1 site
Registry update: 24 Mar 2026
NCT06980597
Recruiting
A Study of OL-108 in Relapsed/Refractory Autoimmune Diseases
Phase 1 · China · 2 sites
Registry update: 20 May 2025
NCT07000682
Recruiting
The Clinical Study on the Treatment of SSc With UTAA91 Injection.
Early phase 1 · China · 1 site
Registry update: 18 Jul 2025
NCT07236970
Recruiting
Multicenter Study on the Development of Pulmonary Arterial Hypertension Screening Models Based on Artificial Intelligence for Patients With Systemic Sclerosis
Not applicable · Spain · 5 sites
Registry update: 19 Nov 2025
NCT06978647
Recruiting
A Clinical Study of YTS109 Cell in R/R Autoimmune Diseases
Phase 1 · China · 1 site
Registry update: 21 Oct 2026
NCT07348263
Recruiting
EFESO: Study on Juvenile Onset Eosinophilic Fasciitis
Not applicable · Germany, Spain, United Kingdom, Croatia, Israel, Italy, Romania, Sweden, Slovenia, United States · 15 sites
Registry update: 11 Mar 2026
NCT04986605
Recruiting
Extracorporeal Photopheresis in Early Diffuse Cutaneous Systemic Sclerosis
Phase 2 · Canada · 1 site
Registry update: 1 Oct 2026
NCT06256575
Recruiting
Study of Diosmin for the Treatment of Digital Ulcers in Systemic Sclerosis
Not applicable · Canada · 5 sites
Registry update: 11 Sept 2026
2024-517283-28-00
Recruiting
T-Guard in dcSSc
Phase 1/2 · Netherlands · 1 site
Registry update: 1 Oct 2026
NCT06947460
Recruiting
CD19-BCMA CART Cell Therapy for Refractory SLE-LN, SSc, and pSS-PAH
Phase 1/2 · China · 1 site
Registry update: 30 Jul 2026

Ordered by registry start date. Freshness and sponsorship never change the order.